SLC6A3 and Alzheimer disease: The relative local brain hypermetabolism investigated with the [18F]FDG-PET method at the level of the SN identified in our study in AD patients with higher CSF DAT levels suggests a relative well-being of the specific area, less affected by degenerative processes and neuronal loss.